In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Andrew McConaghie

Senior Writer

Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.

He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.

Latest From Andrew McConaghie

AZ’s STORM CHASER Falls Short On Ambitious COVID Symptom Goal

AstraZeneca had wanted to outperform Regeneron and Lilly in post-exposure prevention, but will now hope for more durable protection from its long-acting antibody.

Commercial Companies

Novavax’s Latecomer COVID-19 Vaccine Impresses With 90% Efficacy Result

Arriving two to three months later than planned, Novavax’s nanoparticle-based vaccine is still a welcome addition to the field, for both rich and poor countries.

Commercial Companies

Vertex Urged To Target Major M&A After Another Rare Disease Failure

After the failure of a second candidate for alpha-1 antitrypsin deficiency, Vertex may have to put its cash reserves to use in M&A.

Companies Rare Diseases

Aduhelm Approval Is Breakthrough For Neurimmune, Company Which Discovered It

The co-founder of the Swiss company which discovered aducanumab looks back over its 20 year wait for approval, and ahead to future growth plans.

Neurology Commercial

Bayer Advances Parkinson’s Cell And Gene Therapies Into First Human Studies

As Biogen makes history in Alzheimer’s, Bayer is aiming for a breakthrough in Parkinson’s, another major target in neuroscience.

Neurology Gene Therapy

Novartis Challenger To Alexion Advances In Rare Kidney Disease

First-in-class iptacopan could help Novartis expand into kidney disease, and take on Alexion’s blockbuster rare disease franchise.

Companies Commercial
See All
UsernamePublicRestriction

Register